The encephalomyocarditis virus (EMCV) leader sequence is responsible for efficient, cap-independent translation initiation from the viral RNA. It has been used to increase the expression of internal coding regions on polycistronic mRNA encoded by recombinant DNA constructs. We have designed a sequence-replacement-type vector for targeting to immunoglobulin heavy-chain loci in hybridoma cells. Homologous recombination of this vector Introduces a human 'y constant-region sequence linked to the EMCV leader and a neomycin phosphotransferase (neo) gene. The resulting cells express a bicistronic mRNA encoding at the 5' end a chimeric murine VDJI-human Cy1 heavy chain, followed by neo linked to the internal ribosome binding site provided by the EMCV leader. These homologous recombinants express the chimeric heavy chain at levels equivalent to the heavy chain in the parental hybridoma. This strategy of using an EMCV-neo cassette to obtain efficient selectable marker gene expression has potential application to a range of gene targeting vectors.
The alteration of specific chromosomal sequences in mammalian cells by homologous recombination with transfected DNA has proven to be a powerful tool in biology (1) (2) (3) (4) (5) (6) . Many ofthese studies have aimed to inactivate an allele of a specific target gene by inserting a selectable drug marker such as the neomycin phosphotransferase gene (neo) in the same translational frame. This can allow selection for expression of the product of the neo-target gene fusion. Such neo fusion products have frequently been found to confer drug resistance, but the target gene is interrupted and rendered dysfunctional. In some instances, homologous recombination has been used to introduce or correct point mutations in target genes or to create specific fusion genes (7) (8) (9) (10) .
The nontranslated leader sequences of the picornaviruses, including poliovirus and encephalomyocarditis virus (EMCV), function as sites for efficient cap-independent initiation of translation (11, 12) . These sequences have been exploited to generate mammalian cell expression vectors, with an EMCV leader-selectable marker gene cassette placed downstream ofa particular gene on a single bicistronic transcription unit (13) . We reasoned that an EMCV leaderneo cassette could be used to construct sequencereplacement-type vectors for homologous recombination. The EMCV sequence could be used to permit the independent translation of the marker gene on the same transcription unit as the target gene. Therefore, the interruption of the target gene would not be required and, for example, point mutations could be introduced into the target gene. An independent promoter for the marker gene would also not be required, thereby possibly lowering the background of nonhomologous recombinant transfectants.
We have designed a sequence-replacement vector incorporating an EMCV leader-neo cassette that can be used to class-switch immunoglobulin heavy-chain genes. We have found efficient targeting of this vector and the expression of a mouse-human chimeric heavy chain at levels equivalent to the original murine heavy chain in the homologous recombinants.
MATERIALS AND METHODS
Cells and Electroporation. The F8/6.4.6 cell line (provided by P. J. Szklut and W. B. Foster, Genetics Institute) is a murine hybridoma derived from BALB/c spleen cells and the P3X63-Ag8.653 plasmacytoma fusion partner (14) . The IgM(K) antibody produced by this hybridoma is directed against the light chain of human factor VIII. The cells were maintained in RPMI 1640 (GIBCO) supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum (Flow Laboratories) and 1 mM glutamine. The 1OA1C6 Chinese hamster ovary cell line, which expresses recombinant human factor VIII, was grown as described (15) . Electroporation was carried out with 2 x 107 cells in 1 ml as described (16) . After ==48 hr ofgrowth, the neomycin analogue G418 (GIBCO) was added to a final concentration of 1 mg/ml.
Nucleic Acid Manipulations. All DNA manipulations were carried out as described (17 Davies, and R.J.K., unpublished work). This cassette was excised on a Sal I-BamHI fragment consisting of the EMCV leader sequence, as used previously (13) , and an -0.9-kilobase (kb) neo sequence derived from the Mlu I-BamHI neo fragment of pMClneo (19) . The genomic murine a sequence was derived from pA (20 Fig. la . Prior to electroporation, pHR1 was digested with Xho I.
The polymerase chain reaction (PCR) was carried out with reagents and a thermal cycler from Perkin-Elmer/Cetus. PCR was performed on genomic DNA, using the oligodeoxynucleotide primers USNAEMU (5'-GCAGACTAATCT-TGGATATTTGCCC-3') and HGAM-DS (5'-CGAATTCCT-GCCCCAAAGCCAAGGTCAGGCCTGG-3') for 30 cycles of 1 min at 940C, 2 min at 690C, and 3 min at 72TC.
Enzyme-Linked Immunosorbent Assays. ELISAs were carried out as described (16, 21, 22 
HHII4II
IgG1 (yl-chain-specific) conjugated to horseradish peroxidase (Zymed Laboratories) and was calibrated with purified human IgG1 (Chemicon).
RESULTS
The homologous recombination vector designed for these experiments, pHR1 (Fig. la) , contains an "'3.55-kb fragment consisting of human Cy1, the EMCV leader, the neo, marker gene, and the SV40 poly(A)-addition signal, flanked by genomic ,u sequences that can act as targets for homologous recombination. The upstream target homology consists of 1.1 kb 5' of the EcoRI site in the JH-C,, intron, and the downstream target homology extends from this EcoRI site to 3' of the , membrane exons. Upon sequence-replacement-type integration of this construct into a rearranged , heavy-chain allele, a single bicistronic mRNA transcript should be expressed from the endogenous VH promoter. This VDJH rearrangement will be able to splice to the human C,,1 exons. A second coding region, encoding the neo gene product, will conditioned medium (Fig. 2b, lanes 1 and 4) (Fig. 1) . All unrearranged and JHI-JH3 rearrangements of this locus were found by this analysis as an -=2.27-kb fragment, as seen in liver DNA (Fig. 3b, lane 12) (Fig. 3b, lane 6) . These data indicate that the transfected pHR1 DNA has been targeted to the functionally rearranged F8/6.4.6 heavy-chain allele in HR1-21 cells, to give the predicted recombination product shown in Fig. lb .
The murine JH-C, intron of the genomic A clone used to construct pHRl has an -2.5-kb deletion between the intron EcoRI site and the CH1 exon (data not shown). In generating pHR1, the human Cy1-EMCV-neo sequence was inserted into this EcoRI site, resulting in this deletion being located between the neo sequence and C,,. This deletion permits the JH-C,. intron of pHRl to be distinguished from the endogenous ,u sequences in transfected cells. However, in a homologous recombinant clone such as HR1-21, the smaller JH-C, intron will be present only if the 3' site of the sequence replacement is downstream of this intron. Southern blot analysis of the genomic DNA of HR1-21 cells demonstrated that the smaller JH-C,. intron had been retained, indicating that the 3' recombination occurred downstream of the JH-C, deletion in pHRl (data not shown).
The homologous recombination ofthe pHRl sequence into a JH allele was confirmed in HR1-21, HR1-141, and HR1-445 by PCR with genomic DNA. Primers were used that anneal to the sequence immediately upstream of the 5' homology of the construct (primer USNAEMU) and at the 5' end of the human yl sequence used (primer HGAM-DS) (see Fig. 1 ). As predicted, PCR with these primers generated an -1235-bp band that also hybridized with the JH 3' probe by Southern blotting (data not shown). No band was generated by PCR with these primers in F8/6.4.6 DNA.
The specific cellular productivity of the F8/6.4.6 hybridoma and its HR1-21, HR1-141, and HR1-445 derivatives was determined with conditioned media from exponentially growing cultures. The murine ,u-specific ELISA showed that the parental F8/6. Genetics: Wood et al.
Proc. Natl. Acad. Sci. USA 88 (1991) instability (10); cells were cloned from chimeric heavy-chainpositive transfectants that produced the chimeric heavy chain, the murine heavy chain, or both.
In the present study, the frequency of homologous recombinants detected was 1/191 G418-resistant clones. This compares favorably with other reports of, for example, 1/25 and 1/117 for f82-microglobulin (25, 26) , 1/34 for c-abl (27) and 1/950 for hypoxanthine phosphoribosyltransferase (19) . However, unlike the diploid embryonic stem cells used in much previous work, the potentially tetraploid hybridoma used here contains up to four target copies of the JH allele. This may decrease our apparent targeting to the functionally rearranged heavy-chain allele. We had hoped for a greater enrichment of specific targeting events, especially using the EMCV-neo cassette. The background of G418-resistant transfectants was probably increased by incorporating the immunoglobulin heavy-chain enhancer on pHR1 (see Fig. 1 ). This enhancer is known to act as a promoter element, being responsible for initiating sterile ,u transcripts (28) . In addition, the nonspecific integration of this enhancer may activate other promoter elements, causing neo expression. The efficiency ofthis selection system might be improved by omitting this enhancer element from the homologous recombination construct.
There are multiple reasons for genetically engineering the constant regions of monoclonal antibodies (29) (30) (31) (32) (33) . These include the replacement of murine constant-region sequences with human equivalents for purposes of reducing the potential immunogenicity of a therapeutic monoclonal antibody, and the opportunity to modulate its effector-function sequences, such as those responsible for antibody-dependent cellular cytotoxicity. The conventional approaches to generating such chimeric antibodies require the cloning of the functionally rearranged immunoglobulins of a hybridoma, their in vitro manipulation, and the creation of a cell line expressing these genetically engineered immunoglobulins. Such transfected cell lines have generally been found to have specific productivity levels of monoclonal antibody substantially lower than that of the original hybridoma. Although techniques have been developed for increasing this stable production level, these can take a number of months to reach high expression levels (16) .
The pHR1 construct and future derivatives should greatly improve-the ease with which chimeric antibodies can be constructed and expressed at high level. Given the sequences downstream of the JH locus that are common to all heavychain alleles, it should prove possible to class-switch heavychain rearrangements of any isotype with a construct such as pHR1. The same approach can be readily adapted for lightchain loci.
The EMCV-neo cassette has been shown to function efficiently in this work. It is ideal for selecting for recombination events designed not to disrupt completely the functional expression of the target gene or for causing gene fusions such as artificial class switching.
